Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression

Trial Profile

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Bipolar I disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 18 Oct 2022 Results of post hoc analysis of pooled data (NCT01396447, NCT02670538, NCT02670551) assessing which patients with bipolar depression could particularly benefit from 3 mg/d cariprazine presented at the 35th Annual Congress of the European College of Neuropsychopharmacology
    • 05 Oct 2021 Results assessing NCT00488618; NCT01058096; NCT01058668;NCT01396447; NCT02670538 and NCT02670551 assessing efficacy of cariprazine in manic, depressive, and cognitive symptoms in bipolar I disorder in light of its receptor profile, presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
    • 01 Jun 2021 Results of pooled post hoc analysis assessing cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression published in the Journal of Affective Disorders
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top